173 related articles for article (PubMed ID: 21047595)
1. Epilogue: different approaches for prostate cancer screening in the EU?
Schröder FH; Denis L; Roobol MJ
Eur J Cancer; 2010 Nov; 46(17):3120-5. PubMed ID: 21047595
[TBL] [Abstract][Full Text] [Related]
2. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
[TBL] [Abstract][Full Text] [Related]
3. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
4. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer.
Laurila M; van der Kwast T; Bubendorf L; di Lollo S; Pihl CG; Ciatto S; Hugosson J; Määttänen L; Roobol MJ; Kujala PM
Eur J Cancer; 2010 Nov; 46(17):3068-72. PubMed ID: 21047588
[TBL] [Abstract][Full Text] [Related]
5. Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?
Otto SJ; van Leeuwen PJ; Hoekstra JW; Merckelbach JW; Blom JH; Schröder FH; Roobol MJ; de Koning HJ
Eur J Cancer; 2010 Nov; 46(17):3061-7. PubMed ID: 21047587
[TBL] [Abstract][Full Text] [Related]
6. Rural residence and prostate cancer screening with prostate-specific antigen.
Stamatiou K; Skolarikos A
Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
[TBL] [Abstract][Full Text] [Related]
7. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.
Mian BM
Urol Oncol; 2010; 28(3):233-6. PubMed ID: 20097584
[No Abstract] [Full Text] [Related]
9. Two randomized screening trials with prostate cancer mortality, two interim results: a consideration of usual-care window in screening trials.
Song Y
Contemp Clin Trials; 2010 Jul; 31(4):378-80. PubMed ID: 20450987
[TBL] [Abstract][Full Text] [Related]
10. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
[TBL] [Abstract][Full Text] [Related]
11. Lead-time in the European Randomised Study of Screening for Prostate Cancer.
Finne P; Fallah M; Hakama M; Ciatto S; Hugosson J; de Koning H; Moss S; Nelen V; Auvinen A
Eur J Cancer; 2010 Nov; 46(17):3102-8. PubMed ID: 21047593
[TBL] [Abstract][Full Text] [Related]
12. Should prostate-specific antigen screening be offered to asymptomatic men?
van Vugt HA; Bangma CH; Roobol MJ
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Shteynshlyuger A; Andriole GL
J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
[TBL] [Abstract][Full Text] [Related]
15. [Early detection of cancer of the prostate. Pros and cons].
Hoesl CE; Altwein JE
MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen: a new(ish) study.
Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
[No Abstract] [Full Text] [Related]
17. Screening for prostate cancer: prostate-specific antigen testing is not effective.
Hitzeman N; Molina M
Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
[No Abstract] [Full Text] [Related]
18. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
19. Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial.
Malmi H; Ruutu M; Määttänen L; Stenman UH; Juusela H; Tammela TL; Auvinen A
BJU Int; 2010 Aug; 106(4):472-7. PubMed ID: 20184578
[TBL] [Abstract][Full Text] [Related]
20. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
Richard F
Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
[No Abstract] [Full Text] [Related]
[Next] [New Search]
